Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
A model of localised abscess formation was used to establish mixed infections caused by Escherichia coli and Bacteroides fragilis. The beta-lactamase producing, ticarcillin-resistant strains E. coli E96 and B. fragilis VPI 8708 were used to produce one infection, and in another infection, a beta-lactamase hyperproducing strain E. coli 41548 was combined with a ticarcillin-susceptible strain, B. fragilis B3. Treatment, at doses producing clinically achievable concentrations in mouse serum, began 1 h after inoculation, and continued three times daily for four days. Bacterial numbers in infected tissue were measured at intervals. Against both infections, ticarcillin was ineffective in preventing bacterial growth and abscess formation in all mice. Piperacillin prevented abscess formation in 60% of the mice infected with E. coli E96/B. fragilis VPI 8708, and in 40% of those in the E. coli 41548/B. fragilis B3 group. Therapy with ticarcillin/clavulanic acid or cefoxitin reduced the number of both organisms at the site of infection, and thus prevented abscess formation in 100% treated animals.
Beale
A S
AS
Kline Beecham Pharmaceuticals, Betchworth, Surrey, UK.
Gisby
J
J
D000038:Abscess / Q000517:prevention & control; D000818:Animals; D001442:Bacteroides Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D001441:Bacteroides fragilis / Q000254:growth & development; D002440:Cefoxitin / Q000008:administration & dosage / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use*; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use; D013045:Species Specificity; D013982:Ticarcillin / Q000008:administration & dosage / Q000627:therapeutic use*
D002969:Clavulanic Acids; D010406:Penicillins; D002440:Cefoxitin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D010878:Piperacillin